Neil Swift - Takeda Pharmaceutical interim President and CEO
| TAK Stock | USD 13.04 0.03 0.23% |
CEO
Mr. Neil Swift is interim President and Chief Executive Officer of the Company. Neil Swift, BSc has 28 years experience in natural resource exploration and development, ranging from oil and gas to gold. Mr. Swift has focused on Yukonbased projects since 2011, including Brewery Creek, 3 Aces and Howards Pass. Mr. Swift has market experience, having been an officer and director of public companies for 12 years between 1992 and 2004. since 2018.
| Tenure | 6 years |
| Address | 1-1, Nihonbashi-Honcho 2-chome, Tokyo, Japan, 103-8668 |
| Phone | 81 3 3278 2111 |
| Web | https://www.takeda.com |
Takeda Pharmaceutical Management Efficiency
The company has Return on Asset of 0.0261 % which means that on every $100 spent on assets, it made $0.0261 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0276 %, implying that it generated $0.0276 on every 100 dollars invested. Takeda Pharmaceutical's management efficiency ratios could be used to measure how well Takeda Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Takeda Pharmaceutical's Return On Tangible Assets are quite stable compared to the past year. Return On Equity is expected to rise to 0.1 this year, although the value of Return On Capital Employed will most likely fall to 0.05. At this time, Takeda Pharmaceutical's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 16.9 T this year, although the value of Non Current Liabilities Other will most likely fall to about 383.9 B.Similar Executives
| Found 9 records | CEO Age | ||
| Steven Hoerter | Deciphera Pharmaceuticals LLC | 53 | |
| Jack Khattar | Supernus Pharmaceuticals | 63 | |
| Michael Taylor | Deciphera Pharmaceuticals LLC | 63 | |
| Mark Finlay | Evotec SE ADR | N/A | |
| Frank Lee | Pacira Pharmaceuticals | 56 | |
| Rosanne Graham | Evotec SE ADR | N/A | |
| Jenny Yule | Evotec SE ADR | N/A | |
| Mario DPHIL | Evotec SE ADR | 61 | |
| Jack Zhang | Amphastar P | 71 | |
Management Performance
| Return On Equity | 0.0276 | ||||
| Return On Asset | 0.0261 |
Takeda Pharmaceutical Leadership Team
Elected by the shareholders, the Takeda Pharmaceutical's board of directors comprises two types of representatives: Takeda Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Takeda. The board's role is to monitor Takeda Pharmaceutical's management team and ensure that shareholders' interests are well served. Takeda Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Takeda Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ian Clark, Independent Director | ||
| Gregory Hayes, Interim CFO, Corporate Secretary | ||
| Constantine Saroukos, CFO Director | ||
| Salvatore MD, Member Policy | ||
| Neil Swift, interim President and CEO | ||
| C Wasser, Director | ||
| Milano Furuta, Chief Officer | ||
| Lori Walton, Director | ||
| Masami Iijima, Independent Director | ||
| Christophe Weber, President, Chief Executive Officer, Representative Director | ||
| Masahiro Sakane, Independent Chairman of the Executive Board | ||
| Seigo Izumo, Chair Board | ||
| Olivier Bohuon, Independent Director | ||
| Gabriele Ricci, Chief Officer | ||
| Ken Araki, Vice Department | ||
| JeanLuc Butel, Independent Director | ||
| Salvatore Alesci, Member Policy | ||
| Iwaaki Taniguchi, Senior Department | ||
| Michel Orsinger, Independent Director | ||
| Dennis Fentie, Director | ||
| Peter Bures, Director | ||
| Shiro Kuniya, Independent Director | ||
| Emiko Azuma, Independent Director | ||
| Christopher OReilly, Global Finance | ||
| Toshiyuki Shiga, Independent Director | ||
| Dave Glover, IR Contact Officer | ||
| Steven Gillis, Independent Director | ||
| Mwana Lugogo, Chief Officer | ||
| Haruhiko Hirate, Member Board | ||
| Norimasa Takeda, Chief Controller | ||
| Masato Iwasaki, President of Japan Pharma Business Unit, Director | ||
| Yasuhiko Yamanaka, Director | ||
| Emiko Higashi, Independent Director | ||
| Janet LeeSheriff, Director | ||
| Patricia Wilson, Independent Director | ||
| Andrew Plump, President of Research & Development, Vice President of Subsidiary, Director | ||
| Costa Saroukos, Chief Financial Officer, Director | ||
| Tokumasa Takeda, IR Contact Officer | ||
| Yoshiaki Fujimori, Independent Director | ||
| Koji Hatsukawa, Independent Director | ||
| Yoshihiro Nakagawa, Global Counsel |
Takeda Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Takeda Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0276 | ||||
| Return On Asset | 0.0261 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 4.94 T | ||||
| Shares Outstanding | 3.14 B | ||||
| Shares Owned By Institutions | 2.67 % | ||||
| Number Of Shares Shorted | 5.97 M | ||||
| Price To Earning | 27.57 X | ||||
| Price To Book | 0.95 X |
Takeda Pharmaceutical Investors Sentiment
The influence of Takeda Pharmaceutical's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Takeda. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Takeda Pharmaceutical's public news can be used to forecast risks associated with an investment in Takeda. The trend in average sentiment can be used to explain how an investor holding Takeda can time the market purely based on public headlines and social activities around Takeda Pharmaceutical Co. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Takeda Pharmaceutical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Takeda Pharmaceutical's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Takeda Pharmaceutical's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Takeda Pharmaceutical.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Takeda Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Takeda Pharmaceutical's short interest history, or implied volatility extrapolated from Takeda Pharmaceutical options trading.
Currently Active Assets on Macroaxis
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Takeda Pharmaceutical information on this page should be used as a complementary analysis to other Takeda Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Takeda Stock analysis
When running Takeda Pharmaceutical's price analysis, check to measure Takeda Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Takeda Pharmaceutical is operating at the current time. Most of Takeda Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Takeda Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Takeda Pharmaceutical's price. Additionally, you may evaluate how the addition of Takeda Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Global Correlations Find global opportunities by holding instruments from different markets |
Is Takeda Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.12) | Dividend Share 184 | Earnings Share 0.36 | Revenue Per Share 1.3 K | Quarterly Revenue Growth 0.013 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.